David Vogel, CPA

Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order Original Source

Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Dateline City: PRINCETON, N.J. In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM Empliciti-based combination showed improvements across efficacy endpoints, including continued progression-free survival benefit at 18 months…

New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

Dateline City: PRINCETON, N.J. Findings from head-to-head Early AMPLE study are consistent with earlier studies, adding to body of research showing differences between mechanisms of biologic therapies Results suggest that a genetic marker linked to autoantibody production and a more…